Advertisement
Singapore markets close in 5 hours 42 minutes
  • Straits Times Index

    3,336.59
    +3.79 (+0.11%)
     
  • Nikkei

    39,687.40
    +104.32 (+0.26%)
     
  • Hang Seng

    17,718.61
    +2.11 (+0.01%)
     
  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     
  • Bitcoin USD

    63,376.61
    +2,631.90 (+4.33%)
     
  • CMC Crypto 200

    1,315.08
    +31.26 (+2.43%)
     
  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     
  • Dow

    39,118.86
    -45.24 (-0.12%)
     
  • Nasdaq

    17,732.60
    -126.10 (-0.71%)
     
  • Gold

    2,337.10
    -2.50 (-0.11%)
     
  • Crude Oil

    81.92
    +0.38 (+0.47%)
     
  • 10-Yr Bond

    4.3430
    +0.0550 (+1.28%)
     
  • FTSE Bursa Malaysia

    1,594.88
    +4.79 (+0.30%)
     
  • Jakarta Composite Index

    7,115.88
    +52.30 (+0.74%)
     
  • PSE Index

    6,423.39
    +11.48 (+0.18%)
     

With 54% institutional ownership, TELA Bio, Inc. (NASDAQ:TELA) is a favorite amongst the big guns

Key Insights

  • Significantly high institutional ownership implies TELA Bio's stock price is sensitive to their trading actions

  • The top 6 shareholders own 53% of the company

  • Insiders have bought recently

A look at the shareholders of TELA Bio, Inc. (NASDAQ:TELA) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are institutions with 54% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future.

ADVERTISEMENT

In the chart below, we zoom in on the different ownership groups of TELA Bio.

See our latest analysis for TELA Bio

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About TELA Bio?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that TELA Bio does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at TELA Bio's earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Hedge funds don't have many shares in TELA Bio. Looking at our data, we can see that the largest shareholder is Essex Woodlands Management, Inc. with 17% of shares outstanding. With 12% and 10% of the shares outstanding respectively, OrbiMed Advisors LLC and First Light Asset Management, LLC are the second and third largest shareholders. Additionally, the company's CEO Antony Koblish directly holds 0.8% of the total shares outstanding.

We did some more digging and found that 6 of the top shareholders account for roughly 53% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of TELA Bio

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our most recent data indicates that insiders own some shares in TELA Bio, Inc.. As individuals, the insiders collectively own US$2.2m worth of the US$180m company. This shows at least some alignment, but we usually like to see larger insider holdings. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public-- including retail investors -- own 11% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

With an ownership of 34%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Case in point: We've spotted 2 warning signs for TELA Bio you should be aware of.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.